December 05, 2017
1 min read
Save

New device improves TIF procedures for GERD patients

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

EndoGastric Solutions announced the launch of its new device, EsophyX Z+, which offers expanded endoscope compatibility and supports the transoral incisionless fundoplication 2.0 procedure to reconstruct the gastroesophageal valve and restore its function as a reflux barrier.

Michael Murray, MD , FACS, from Northern Nevada Medical Center, and Kenneth Chang, MD, gastroenterologist at UC Irvine Health, were the first to perform the transoral incisionless fundoplication (TIF) 2.0 procedure using the new EsophyX Z+ device, according to the release.

“GERD is a chronic condition and proton pump inhibitors do not control symptoms in about one-third of patients,” Murray said in the release. “The design of the new EsophyX Z+ device makes performing TIF 2.0 procedures technically easy and produces a consistent and effective fundoplication thus providing an effective alternative to prescription medications and traditional surgical procedures.”

The EsophyX Z+ device used a transoral approach, which allows physicians to rebuild the gastroesophageal valve with a partial fundoplication technique that secures the tissue with dual deployment of SerosaFuse Implantable Fasteners, according to the release.

Building on the first EsophyX device, cleared by the FDA in 2007, EndoGastric Solutions launched the third generation EsophyX Z model platform in 2015, per the release. Today, using the most advanced technology, EsophyX Z+ offers surgeons and gastroenterologists the chance to use a broader selection of standard endoscopes to treat the underlying anatomical cause of GERD.

“The robust collection of clinical data and recent positive policy coverage announcements support the TIF 2.0 procedure as an established treatment option for patients who wish to eliminate or discontinue PPI use and avoid surgery for acid reflux,” Chang added. “This newest design iteration allows for maximal visibility using a standard endoscope combined with almost effortless and confident deployment of fasteners. GI endoscopists and surgeons should consider the TIF procedure in patients seeking a less invasive, proven GERD treatment solution.”

Disclosures: Healio Gastroenterology and Liver Disease was unable to confirm any relevant financial disclosures at the time of publication.